title: Selective venous catheterization for the localization of phosphaturic mesenchymal tumors.
abstract: Tumor-induced osteomalacia (TIO) is characterized by renal phosphate wasting, hypophosphatemia, and aberrant vitamin D(3) metabolism and is caused by fibroblast growth factor 23 (FGF-23)-producing mesenchymal tumors, which are often difficult to locate. We investigated the utility of selective venous sampling in tumor localization. The primary endpoint was identification of the FGF-23 concentration ratio between the venous drainage of the tumor bed and the general circulation that was diagnostic of the location of an FGF-23-secreting tumor. Fourteen subjects underwent 15 sampling procedures after functional and anatomic imaging studies. Subjects fit into three imaging categories: no suspicious site, multiple sites, and single site (positive controls). FGF-23 levels were measured by ELISA. Suspicious tumors were resected for diagnosis, confirmation, and cure. In subjects with a positive venous sampling study and subsequent cure, a minimum ratio of 1.6 was diagnostic. In 7 of 14 subjects there was suggestive imaging, a diagnostic ratio, and an associated TIO tumor (true positive). Four of these required complicated resection procedures. In 4 of 14 subjects with no suspicious site on imaging studies, an FGF-23 diagnostic ratio was not detected (true negative). Biopsy or resection of a single lesion in 2 of 14 subjects with a diagnostic ratio failed to identify a TIO tumor (false positive). A diagnostic FGF-23 ratio was absent in 1 of 14 subjects whose tumor was a single highly suspicious lesion on imaging studies (false negative). These data yield a sensitivity of 0.87 [95% confidence interval (CI) 0.47-0.99] and a specificity of 0.71 (95% CI 0.29-0.96). Selective venous sampling for FGF-23 was particularly useful in subjects with multiple suspicious sites or an anatomically challenging planned resection but not in the absence of a suspicious lesion on imaging studies.
authors: Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892-4320, USA.
authors: Panagiota
authors: P
authors: Andreopoulou
authors: Claudia E
authors: CE
authors: Dumitrescu
authors: Marilyn H
authors: MH
authors: Kelly
authors: Beth A
authors: BA
authors: Brillante
authors: Carolee M
authors: CM
authors: Cutler Peck
authors: Felasfa M
authors: FM
authors: Wodajo
authors: Richard
authors: R
authors: Chang
authors: Michael T
authors: MT
authors: Collins
references: Nat Genet. 2006 Nov;38(11):1310-5
references: 17033621
references: Endocr Pract. 2008 Apr;14(3):362-7
references: 18463045
references: Am J Surg Pathol. 2004 Jan;28(1):1-30
references: 14707860
references: Nat Genet. 2000 Nov;26(3):345-8
references: 11062477
references: Biochem Biophys Res Commun. 2000 Oct 22;277(2):494-8
references: 11032749
references: J Neurosurg Spine. 2009 Nov;11(5):600-4
references: 19929364
references: J Bone Miner Res. 2007 Jun;22(6):931-7
references: 17352646
references: JAMA. 2005 Sep 14;294(10):1260-7
references: 16160135
references: Kidney Int. 2000 Jan;57(1):9-18
references: 10620182
references: N Engl J Med. 2011 Oct 27;365(17):1625-35
references: 22029985
references: J Clin Endocrinol Metab. 2004 Aug;89(8):3979-82
references: 15292336
references: J Clin Invest. 2003 Sep;112(5):683-92
references: 12952917
references: J Clin Endocrinol Metab. 2007 Jun;92(6):2374-7
references: 17374707
references: Intern Med. 2008;47(10):957-61
references: 18480582
references: Bone. 2004 Nov;35(5):1192-9
references: 15542045
references: Intern Med. 2008;47(7):637-41
references: 18379151
references: Matrix Biol. 2004 Nov;23(7):421-32
references: 15579309
references: Proc Natl Acad Sci U S A. 2001 May 22;98(11):6500-5
references: 11344269
references: Eur J Endocrinol. 2008 Mar;158(3):431-7
references: 18299479
references: N Engl J Med. 2003 Apr 24;348(17):1656-63
references: 12711740